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The  existence  of  a  link  between  estrogen  deprivation  and  osteoarthritis  (OA)  in
postmenopausal women suggests that 17-estradiol (17-E2) may be a modulator of cartilage
homeostasis.  Here,  we demonstrate  that  17-E2 stimulates,  via its  receptor  hER66 (human
estrogen  receptor   66),  type  II  collagen  expression  in  differentiated  and  dedifferentiated
(reflecting the OA phenotype) articular chondrocytes.  Transactivation of type II collagen gene
(COL2A1) by ligand independent  transactivation domain (AF-1) of hER66 was mediated by
‘GC’ binding sites of the -266/-63 bp promoter,  through physical  interactions  between ER,
Sp1/Sp3,  Sox9  and  p300,  as  demonstrated  in  ChIP  and  Re-ChIP  assays  in  primary  and
dedifferentiated cells. 17-E2 and hER66 increased the DNA-binding activities of Sp1/Sp3 and
Sox-9 to both  COL2A1  promoter and enhancer regions. Besides, Sp1, Sp3 and Sox-9 siRNAs
prevented hER66-induced  transactivation of  COL2A1, suggesting that these factors and their
respective  cis-regions  are  required for  hER66-mediated  COL2A1 up-regulation.  Our results
highlight  the  genomic  pathway by which  17-E2 and hER66 modulate  Sp1/Sp3 heteromer
binding activity and simultaneously participate in the recruitment of the essential factors Sox-9
and  p300  involved  respectively  in  the  chondrocyte  differentiated  status  and  COL2A1
transcriptional  activation. These  novel  findings  could  therefore  be  attractive  for  tissue
engineering  of  cartilage  in  OA,  by  the  fact  that  17-E2  could  promote  chondrocyte
redifferentiation.
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Key Messages
 17-E2 up-regulates type II collagen gene expression in articular chondrocytes.
 An ER66/Sp1/Sp3/Sox-9/p300 protein complex mediates this stimulatory effect.
 This heteromeric complex interacts and binds to Col2a1 promoter and enhancer in vivo.
 Our findings highlight a new regulatory mechanism for 17-E2 action in chondrocytes. 
 17-E2 might be an attractive candidate for cartilage engineering applications. 
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Introduction
Mature articular cartilage harbours a predominant cell type, the chondrocyte,  which is
responsible for the extracellular matrix (ECM) turnover regulation by synthesizing and secreting
cartilage-specific matrix markers such as type II collagen and large aggregating proteoglycans,
aggrecans.  The  role  played  by  type  II  collagen,  a  phenotypic  marker  of  healthy  articular
cartilage,  in  the  homeostasis  of  ECM  is  critical,  as  illustrated  by  the  loss  of  the  physico-
mechanical  properties  of  the  tissue  leading  to  a  variety  of  joint  diseases  such  as  OA  and
rheumatoid arthritis. During OA development and/or when cells are cultured as monolayers or
passaged,  chondrocytes  undergo  de-differentiation  process:  they  lose  their  normal  cartilage
phenotype and have been found to progressively reduce their type II collagen synthesis in favour
of non-specific articular cartilage collagens (isotypes I, III, V and X) . As a consequence, it is of
special interest to get insight into the molecular mechanisms that govern type II collagen gene
expression, in order to better  understand the process of phenotype alteration in chondrocytes
during OA.
Type  II  collagen  is  first  synthesized  as  a  procollagen triple-helix  molecule  including
identical  1(II)  chains  encoded  by  the  COL2A1 gene  .  Sequence  analysis  of  COL2A1 has
revealed crucial DNA regulatory elements within both the short promoter and the first intron
regions  (Fig. 1). Thus, several binding sites of the intronic enhancer have been shown to interact
with  transcription  factors,  such  as  Sox-9,  Sox-6,  and  L-Sox-5  acting  cooperatively  and
consequently activating expression of  COL2A1 in 10T1/2 and MC615 cells  .  Moreover, zinc
finger transcription factors Sp1, Sp3 and C-Krox are able to bind not only to this region but also
to several DNA sites localized in a 266-bp promoter of COL2A1. Interestingly, Sp1 was found to
be a potent activator of COL2A1 transcription by binding to GC-rich sequences in the promoter
and in the intronic enhancer  whereas Sp3 prevents this action by competing Sp1 for its  GC
responsive elements .
From epidemiological studies, the prevalence of OA is known to increase dramatically in
women  around the  age  of  50,  coinciding  with  the  onset  of  menopause,  and  suggesting  the
potential for estrogens in preventing OA. The menopause is associated with an increase in the
urinary levels of CTX-II, a telopeptide fragment of type II collagen, and this increase correlates
with collagen II degradation and joint damage, and can be antagonized by estrogens . Although
there are some conflicting results among these studies, most of the clinical observations show
that hormone replacement therapy (HRT) is associated with reduced severity and prevalence of
OA in postmenopausal women . Another study demonstrated that  the localized production of
17-E2 by synovial cells inhibits IL-6 secretion by osteoarthritic chondrocytes in postmenopausal
women  highlighting the anti-inflammatory properties  of 17-E2.  This chondroprotective effect
of  HRT  was  confirmed  in  animal  models.  For  instance,  a  long-term  (3  years)  estrogen
replacement  therapy  in  ovariectomized  monkeys  significantly  decreases  the  severity  of  OA
lesions by maintaining intact articular cartilage structure and reducing number of osteophytes,
chondrocyte cloning and proteoglycan loss . As estrogens are known to down-regulate the matrix
metalloproteinases  (MMPs)  that  are  critical  for  cartilage  collagenolysis,  the  main  effect  of
estrogens relies upon the inhibition of the catabolic processes in articular chondrocytes. However
17-E2 can also stimulate the anabolic pathway by  interacting with synthesis and secretion of
transforming  growth  factor-1  (TGF-1)  and  insulin-like  growth  factor-I  (IGF-I).  Indeed,
compared with chondrocytes from non-treated ovariectomized monkeys, 17-E2-treated animals
have  two-fold  higher  synovial  fluid  levels  of  IGF-I  .  This  growth  factor  is  critical  for  the
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regulation of chondrocyte proliferation, aggrecan synthesis and COL2A1 expression  as well as
TGF- whose expression is influenced by  17-E2  in dose-dependent and biphasic manner . In
this  context,  molecular  mechanisms  by which  estrogens  mediate  a  chondroprotective  action
through type II collagen regulation remain to be elucidated.
Identification  of  two isoforms  of  estrogen  receptor,  alpha  (ER)  and  beta  (ER),  in
articular  chondrocytes  from several  species  including  rabbits   and  human  ,  provides  strong
evidence  that  cartilage  can  respond  to  estrogens.  Deletion  of  both  ERs  leads  to  increased
osteophytosis  in  six-month-old  knockout  mice  .  The  majority  of  ERs  are  nuclear  proteins
belonging to the steroid receptor  family of transcription factors,  structurally organized in six
distinct domains (A to F). According to the ‘classical genomic model’, ligand-activated ER
binds to specific DNA sequences called ‘Estrogen Responsive Elements’ (ERE); so that two
transactivation  functions,  AF-1  (ligand  independent)  and  AF-2  (ligand  dependent),  located
respectively in B and E receptor domains, act cooperatively to modulate transcriptional activity
of 17-E2-target genes. Nevertheless, 35% of the categorized human 17-E2-responsive genes
are  transcribed  via indirect  ER-DNA  association  through  protein-protein  interactions  with
several trans factors such as Sp1, nuclear factor-kappaB (NF-B) or activator protein-1 (AP-1) .
For instance,  Sp1 and ER can form a complex  in vivo to mediate  E2-induced activation of
kisspeptin 1 promoter in hypothalamic GT-1 cells .
The 46 kDa hER isoform (hER46), which has been first identified in MCF-7 breast
carcinoma  cell  line, lacks  the  N-terminal  173  amino  acids  of  A  and  B  domains  and  is
consequently devoided of AF-1 transactivation sequence. In a cell context where AF-1-mediated
transactivation  predominates  over  AF-2,  hER46  is  an  effective  competitive  inhibitor  of
hER66. Indeed, when both isoforms are co-expressed (as it  seems to be the most  frequent
situation  in  vivo),  hER46  efficiently  represses  the  transcription  of  estradiol-target  genes
induced by hER66 by suppressing AF-1 activity of full-length estrogen receptor . Expression of
hER46 was also reported in human primary osteoblasts at similar levels compared to hER66 .
To  our  knowledge,  no  information  exists  on  the  exact  function  of  hER46  in  articular
chondrocytes, except our previous study demonstrating that, unlike hER66, hER46 isoform is
not  able  to  stimulate  UDP-glucose  dehydrogenase  gene  activity  in  primary  rabbit  articular
chondrocytes .
In  the  present  study,  we aimed to investigate  the role  of  17-E2  in  the regulation of
COL2A1 expression in rabbit articular chondrocytes (RAC). We demonstrated for the first time
that COL2A1 up-regulation by 17-E2 involves a -266/-63 bp promoter region and that this effect
was  mediated  by  AF-1  region  of  hER66  in  both  differentiated  and  dedifferentiated
chondrocytes.  Moreover,  we  showed  that  hER66  requires  Sp1,  Sp3,  Sox-9  and  p300
cooperation to increase COL2A1 transcription in RAC. Therefore, association of 17-E2/hER66
complex to COL2A1 regulatory sequences may contribute to reverse the loss of type II collagen




Chemical  reagents  were of the highest grade from Sigma-Aldrich Co (Saint  Quentin-
Fallavier,  France),  as well  as  IL-1,  TGF-1, tamoxifen and mithramycin  A. Trichloroacetic
acid, Tris and glycine were purchased from Acros Organics (Noisy-le-Grand, France). Fetal calf
serum (FCS), Dulbecco’s modified Eagle’s medium (DMEM), di-deoxynucleosidetriphosphate
(dNTPs), RNAse inhibitor, trypsin and phosphate-buffered saline (PBS) were purchased from
Invitrogen (Cergy-Pontoise, France). Protein Assay kit was from Bio-Rad (Marnes-la-Coquette,
France). 2X SYBR Green Master Mix was purchased from Applied Biosystems (Courtabœuf,
France). All the primers and oligonucleotides used in this study (Real-time PCR, EMSAs, ChIP)
were synthesized by Eurogentec Corporation (Seraing, Belgium) (Table 1).  [3H]proline and [-
32P]dATP  were purchased from PerkinElmer Life Sciences (Courtabœuf, France) and double-
charcoal treated FCS was from Abcys (Paris, France).
 
Antibodies
Rabbit  polyclonal  anti-type  II  collagen  was  from  Novotec  (Lyon,  France).  Rabbit
monoclonal anti--actin (C-2), anti-ER (MC-20), anti-Sp1 (PEP-2), anti-Sp3 (D-20), anti-Sox-
9 (P-20), anti-p300 (N-15), anti RNA polymerase II (H-224) and horseradish peroxidase (HRP)-
conjugated goat anti-rabbit were purchased from Tebu-Bio (Le Perray en Yvelines, France). 
Chondrocyte culture
RAC were isolated from articular cartilage slices of shoulders and knees of 3-week old
male  rabbits,  by  sequential  digestion  with  hyaluronidase  (1088  U/ml,  Serva,  Heidelberg,
Germany),  trypsin  (124  U/ml,  Coger,  Paris,  France)  and  type  I  collagenase  (410  U/ml,
Invitrogen). The cells were seeded generally at 3.5   105  cells per 9.6-cm2  dishes or 1.5   106
cells  per  55-cm2 dishes  in  2  or  8  ml  of  DMEM  containing  10%  heat-inactivated  FCS,
supplemented with glutamine (2 mM), fungizone (0.25 µg/ml) and antibiotics: penicillin (100
UI/ml) and erythromycin (100 µg/ml). They were grown for 8-12 days at 37°C in a 5% CO2
humidified atmosphere, with medium change every 2-3 days. For dedifferentiation, in order to
mimic some of OA phenotype characteristics (i.e. decrease of type II and increase of type I
collagen productions), RAC cultures were passaged three times with 0.25% trypsin (Invitrogen)
after reaching confluency. When chondrocytes were treated by 17-E2 (Sigma-Aldrich Co),  they
were  incubated  in  phenol  red-free  DMEM  medium  supplemented  with  2% double-charcoal
treated  FCS.  In  some  experiments,  articular  chondrocytes  were  incubated  for  24  h  with
tamoxifen (1 µM), a partial  antagonist  of estrogen receptors or mithramycin  A (100 nM), a
binding inhibitor to GC-rich sequences, in the same medium as for 17-E2 treatment. MCF-7 cell
line was cultured in the same conditions as primary RAC.
Collagen labeling and assay
To  assay  newly  synthesized  collagen,  series  of  chondrocytes  in  6-well  plates  were
transiently transfected, at 80% confluency, with 10 µg of the expression vector pCR3.1-hER66
5
or pCR3.1-hER46, encoding the long or the short estrogen receptor   isoforms respectively
(pCR3.1 plasmid was used as control). Second series were not transfected and used to study the
effect of increasing concentrations of 17-E2. Fifteen hours later, all the cell culture media were
changed to  10% FCS/DMEM supplemented  with  100 µg/ml  sodium ascorbate.  Twenty-four
hours later, cells were incubated for 24 h in 2% double-charcoal treated FCS/DMEM medium
supplemented with 50 µg/ml sodium ascorbate, 100 µg/ml  -aminopropionitrile and 2 µCi/ml
[3H]proline, containing or not 17-E2 (0-5 nM), TGF-1 (3 ng/ml) or IL-1 (1 ng/ml). Only the
chondrocytes which were not submitted to transient transfection experiments were treated by the
hormone  or  the  cytokines.  Twenty-four  hours  after  treatments  or  48 h post-transfection,  the
culture medium and the cell extracts were collected, and the amount of labeled collagen was
assayed as previously described .
Western-blotting
Twenty-four hours after incubation with 17-E2  or 48 h post-transfection, RAC cultures
were washed three times with PBS and whole cell extracts were prepared as previously described
. The cell extract-associated proteins (20 µg) were resolved on a 8% polyacrylamide gel, using
1% SDS/Tris  glycine  buffer.  The  proteins  were  then  electrotransferred  onto  polyvinylidene
difluoride (PVDF) membrane (Millipore, Molsheim, France). Free protein-binding sites of the
PVDF membranes were blocked for 1 h in Tris buffer saline (TBST, 20 mM Tris, 137 mM NaCl,
0.1% Tween 20) containing 10% non-fat dry milk and the membranes were incubated with anti-
type  II  procollagen,  anti-ER,  anti-Sp1,  anti-Sp3 or  anti--actin  antibodies.  After  overnight
incubation at 4°C, the membranes were rinsed and incubated for 1 h with a secondary antibody
(HRP-conjugated goat  anti-rabbit  antibody at  1:6000 dilution).  Protein signals  were revealed
using a Western-blotting Chemiluminescence Luminol Reagent (Tebu-Bio) and quantified with
the Image Quant software (Amersham Biosciences, Orsay, France). The type II collagen signal
was normalized to that of -actin.
Real-time RT-PCR
Total  RNAs  were  extracted using  TRizol Reagent,  according  to  the  manufacturer’s
instructions (Invitrogen). Two µg of RNAs, previously treated with DNase I (Invitrogen) were
reverse transcribed into cDNA using 50 pmoles of oligo dT, 5 mM of each dNTPs, reverse
transcriptase buffer 5X, 40 units/µl  of RNase inhibitor and 200 units/µl of Moloney Murine
Leukemia Virus enzyme (Invitrogen) in a final volume of 25 µl. Real-time PCR amplifications
were carried out with 5 µl of cDNA (diluted 1:100) on an ‘ABI Prism 7000 sequence detection
system’ (Applied Biosystems), using sequence-specific primers (Table 1) and 2X SYBR Green
Master Mix protocol as outlined by the manufacturer. Each sample was run in triplicate, and
analysis of relative gene expression was done by using the 2-CT method.
Transient transfection experiments
Eighty  percent  confluent  RAC in  six-well  plates  were  transiently  transfected  by  the
calcium phosphate precipitation method. Luciferase reporter plasmids (10 µg) containing various
deletions of  COL2A1 promoter/first  intron were co-transfected with 10 µg of pCR3.1 vector
containing  or  not  the cDNA encoding the  human estrogen receptor   (hER).  The  reporter
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constructs  pGL2-3.374  kb,  pGL2-3.316  kb,  pGL2-0.387  kb  and  pGL2-0.110  kb  cover,
respectively, the -932/+2842 bp, -932/+2384 bp, -266/+121 bp and -63/+47 bp of the promoter
and first intron of COL2A1, as previously described . Expression vectors used for hER encode
either long form of estrogen receptor  or short mutated inoperative form of the receptor (A/B
domain  deleted),  denoted hER66 or hER46 respectively. After  12-15 h,  the medium was
changed to 10% FCS/DMEM. Twenty-four  hours  later,  the  samples  were harvested and the
protein  content  and  luciferase  activities  were  assayed  on  whole  cell  extract  (Promega,
Charbonnières les Bains, France) in a luminometer (Berthold Lumat LB 9501, Bad Wildbad,
Germany). The protein amount was determined by the Bradford colorimetric method (Bio-Rad).
Luciferase activities were normalized to protein content and represented as mean ± S.D. of three
independent samples.  For all the transcriptional activity assays, the Escherichia coli lacZ gene,
encoding  β-galactosidase  (β-gal  vector)  was  systematically  transfected  in  combination  with
COL2A1 reporter  constructs  and  hERα  expression  plasmids  to  achieve  for  transfection
efficiencies. In an additional experiment (Fig. 5C), 10 µg of pGL2-0.387 kb COL2A1 reporter
construct  was  co-transfected  with  2  µg  of  siRNA  directed  against  ER (Tebu-Bio).  The
corresponding negative siRNA (scrambled sequence of the siRNA target) was used as control.
After 15 h of transfection, the medium was changed to 10% FCS/DMEM. Twenty-four hours
later, the samples were harvested and analyzed as described above.
Small interfering RNAs (siRNAs) transfection
In  knock-down experiments,  hER66 and  hER46  expression  vectors  were  also  co-
transfected with siRNAs (Tebu-Bio) directed against the human Sp1, Sp3 and Sox-9 mRNAs. At
80%  confluency,  RAC  were  transiently  transfected  by  the  calcium  phosphate  precipitation
method using 5 µg of hER66 or hER46 expression vectors in combination with 2 µg of Sp1,
Sp3 or Sox-9 siRNAs. After an overnight transfection period, the cells were incubated for 24 h in
absence or in presence of 17-E2.  The corresponding insertless plasmid pCR3.1 and negative
siRNA were used as controls. Relative expression of Col2a1, Sp1, Sp3, Sox-9 and hER66 genes
was determined by real-time RT-PCR.
Electrophoretic Mobility Shift Assays (EMSAs)
Nuclear proteins from RAC treated or not with increasing concentrations of 17-E2 or
transfected with estrogen receptors expression vectors, as described above, were extracted by a
minipreparation procedure . EMSAs were performed with oligonucleotides presented in Table 1,
which  were  end-labeled  with  [-32P]dATP  using  T4  polynucleotide  kinase  (Promega).  RAC
nuclear  extracts  (10  µg)  were  incubated  for  20  min  at  room temperature  with  2  fmoles  of
radioactive probe in a specific binding buffer (for +2817/+2846 probe, -96/-66 probe, -225/-188
probe and ERE/mutant ERE probes, 20% glycerol, 40 mM Tris pH 7.5, 2 mM DTT, 200 mM
NaCl, 0.01% BSA, 0.2% Nonidet P-40; for +2353/+2415 probe or +2383/+2415 probe, 20 mM
HEPES pH 7.9, 50 mM KCl, 10% glycerol, 0.5 mM EDTA, 0.5 mM DTT, 1 mM PMSF, 0.05%
Nonidet P-40) in presence of 2 µg of poly(dI-dC) (for +2817/+2846 probe, -96/-66 probe, -225/-
188 probe or ERE probes)  or 2 µg of poly(dG-dC) (for  +2353/+2415 or +2383/+2415 probe),
used  as  non specific  DNA competitors.  For  EMSAs performed  with  ERE and mutant  ERE
probes,  samples  were submitted for 20 min to a supplemental  incubation in the presence or
absence of a ER antibody (4 µg) or molecular excess ( 100) of wild type non labelled ERE
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probe (cold probe). Samples were fractionated on a 7% polyacrylamide electrophoresis gel for 2
h  at  150 V in  0.5  X TBE buffer  (Tris  borate  450 mM,  10 mM EDTA) and visualized  by
autoradiography.
Immunoprecipitation assays
200 µg of protein nuclear extracts  from control or 1 nM 17-E2 treated chondrocytes
were pre-cleared with 2.5 mg of protein A-Sepharose (Sigma-Aldrich Co) for 2 h at 4°C. Pre-
cleared extracts, relieved of protein A-Sepharose, were immunoprecipitated for 15 h at 4°C using
an  anti-Sp1  antibody.  Then,  protein-antibody  complexes  were  captured  by  adding  3  mg  of
protein A-Sepharose and unbound proteins were removed by washing the solid phase four times
with  hypertonic  lysis  buffer  (119  mM  Tris  pH  6.8,  5%  glycerol,  0.4%  SDS,  1%  -
mercaptoethanol,  0.02% bromophenol  blue).  Samples  were then resuspended in 50 µl of 2X
sample loading buffer (20 mM HEPES, 25% glycerol, 1 mM MgCl2, 420 mM NaCl, 0.2 mM
EDTA) and boiled for 5 min. Remaining nuclear proteins were centrifuged at 14000 g for 2 min
(4 °C) and supernatants were submitted to Western-blotting.
Chromatin Immunoprecipitation assays (ChIP)
RAC,  incubated  or  not  with  17-E2  (1  nM),  were  cross-linked,  scraped,  and  lysed
according to the manufacturer’s instructions. Resulting chromatin was used in ChIP assays using
a commercial  chromatin  immunoprecipitation  kit  (Active Motif,  Rixensart,  Belgium).  In  Re-
ChIP  experiments,  a  supplemental  overnight  immunoprecipitation  with  ER antibody  was
performed to isolate specific DNA-protein complexes. ChIP primers (Table 1) were designed to
amplify in PCR a 171 bp specific fragment of the COL2A1 core promoter or a 229 bp fragment
of the COL2A1 intronic enhancer region.
Statistical analysis
Results  were representative of at least three experiments with similar results, performed
in triplicates  unless otherwise precisions.  Statistically significance was assessed by using the
Student’s t test. Statistically significant differences were set at ***p<0.001, **p<0.01 and *p<0.05.
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Results
17-E2 and its  receptor  hER66 stimulate  type  II  collagen  production  in  primary  articular
chondrocytes
We first  determined  whether  17-E2 and  its  receptors  hER66 or  hER46 modulate
collagen synthesis in primary RAC. 17-E2  was found to enhance total collagen neosynthesis
(Fig. 2A), mainly composed of type II collagen (80%) in primary RAC. The stimulating effect of
the hormone, mainly observed in the cell extract associated fraction compared to supernatant
culture medium,  was biphasic with a maximal  peak for concentrations  of 0.5 and 2 nM. As
expected, incubation of the cells with TGF-1 resulted in a marked increase (about 175%) of
[3H]proline  labeling  in  the  cell  extract  fraction,  whereas  interleukin-1 (IL-1)  reduced  the
incorporation to 50% of the control value. Next, we found that hER66 stimulated total cell
extract and culture medium associated collagen production in RAC whereas mutated receptor
hER46 did not induce any significant  effect  on both fractions (Fig.  2B). However,  a weak
enhancing effect of hER46 was observed on the total production of neosynthesized collagens.
Then, we specifically investigated the effect of 17-E2 on type II collagen synthesis by Western-
blotting. By comparison to untreated cells, we found that 17-E2  stimulated type II procollagen
protein synthesis by approximately 100% (Fig. 3A) in primary RAC. In the same way, forced
expression of hER66 induced a two-fold increase in type II collagen protein amounts whereas
hER46 slightly enhanced these amounts by approximately 30% (Fig. 3C). In dedifferentiated
chondrocytes,  a  low  dose  of  17-E2  (0.01  nM)  remained  activator  for  type  II  procollagen
production, but to a lower level compared to primary RAC, since the induction produced by the
hormone was only of 22% (Fig. 3B). In contrast, for higher concentrations (0.1 nM-5 nM), 17-
E2 significantly decreased type II collagen amounts in a dose-dependent manner.
17-E2 and its  receptor  hER66  up-regulate Col2a1 mRNAs  steady-state  levels  in  primary
articular chondrocytes
Similarly to collagen neosynthesis results, the steady-state levels of Col2a1 mRNAs were
increased under 17-E2 treatment in a biphasic manner (i.e. only doses ranging between 1 and 5
nM  increased  the  amounts  of  type  II  procollagen  transcripts)  (Fig.  4A),  suggesting  a
transcriptional control. As shown in Fig. 4B, the stimulatory effect of 17-E2 was dependent on
estrogen receptors. Indeed, the addition of tamoxifen, a partial antagonist of estrogen receptors,
induced about 55-60% decrease of type II collagen mRNAs steady-state levels and prevented the
stimulatory action of 17-E2  on the transcripts levels. According to these results, we found that
intermediate  amounts  (5-10  µg)  of  hER66  strongly  increased Col2a1 mRNAs steady-state
levels  whereas  higher  quantity  (15  µg)  of  expression  vector  induced  an  approximate  30%
decrease of mRNAs levels (Fig. 4C and 4D). Moreover, these last data have a similar pattern as
those observed in Panel A where RAC were incubated with 17-E2, indicating once again that the
hormone mediates its effects on Col2a1 gene through hER66.
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A -266/-63-bp region of COL2A1 promoter mediates the up-regulatory effect of hER66 in both
primary and dedifferentiated RAC
To  delineate  the  genomic  sequences  involved  in  hER-mediated  effect,  in  both  the
promoter  and/or  the  first  intron  regions  of  COL2A1,  we  co-transfected  different  COL2A1
reporter constructs together with hER66 or hER46 expression vectors. Whatever the construct
size,  the  transcriptional  activity  of  the  reporter  gene  was  always  found  to  be  enhanced  by
hER66, compared to the respective controls, except for the shortest construct -63/+47 bp (Fig.
5A and 5B).  Therefore,  it  is  likely that  a minimal  -266/-63 bp region of  COL2A1 promoter
mediates hER66-induced COL2A1 transactivation in both primary and dedifferentiated RAC.
Moreover,  hER46 isoform did not significantly modify the basal expression of the reporter
COL2A1 (except for the shortest construct -63/+47 bp), indicating that hER66 stimulation of
COL2A1 is  specific  of  this  isoform  and  depends  directly  on  AF-1  ligand-independent
transactivation domain of hER.
Then, in order to check whether ER66 was involved in basal transregulation of type II
collagen gene, we co-transfected the pGL2-0.387 kb COL2A1 reporter construct together with an
ER specific siRNA. ER66 silencing was accompanied by a 75% down-regulation of COL2A1
transcription levels compared to control siRNA (Fig. 5C), demonstrating the central role played
by ER66 to mediate 17-E2-induction of COL2A1 transcription in articular chondrocytes.
Additionally, since no ERE is present in the -266/-63-bp sequence of COL2A1 and since
we have identified several GC boxes binding Sp1 and Sp3 in this region , experiments were
performed with mithramycin A, a binding inhibitor to GC-rich sequences. The objective of such
an assay was to determine if hER66 effect on COL2A1 could involve a protein/protein type of
interaction  with Sp1/Sp3, these latter  trans factors binding to their  proper  cis elements.  The
results showed that, not only incubation of primary RAC with mithramycin A strongly decreased
basal  expression of  Col2a1 mRNAs but  also  prevented,  at  least  in  part,  the  17-E2-induced
stimulation  of  type  II  collagen mRNAs expression  (Fig.  5D).  Thus,  these  data  indicate  that
hER66 has a transactivating effect on COL2A1, probably through an interaction with Sp factors
binding to their cognate cis elements.
17-E2 increases the DNA binding activity of Sp1 and Sp3 to the COL2A1 proximal promoter
As  previously  shown  in  Fig.  5A/B,  17-E2 and  its  receptor  hER66  stimulate
transcriptional  activity  of  COL2A1 by the -266/-63 bp region.  Six specific  C-Krox/Sp1/Sp3-
binding sites have been characterized in this promoter region (Fig. 1) . To determine the capacity
of 17-E2 to modulate Sp1/Sp3-binding sites activity of COL2A1, EMSAs were carried out with
the -96/-66 and -225/-188 COL2A1 radiolabeled oligonucleotides which were already proven to
contain both one GC-rich sequence (Fig. 6C). As shown in Fig. 6A and 6B, the binding activity
of Sp1/Sp3 proteins involved in the formation of the different complexes was increased by 17-
E2 in  a  biphasic  manner.  Indeed,  the  intermediate  concentrations  0.1  and  1  nM  induced  a
significant  increase  in  the  Sp1/Sp3  binding  activities  to  -96/-66  and  -225/-188  COL2A1
radiolabeled probes whereas lower or higher doses of the hormone induced a weaker effect.
These data highlight the potential for 17-E2 to increase transcriptional activity of COL2A1 by
probably promoting the binding of Sp1, and to a lesser extent, of Sp3 to COL2A1 promoter.
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17-E2 and its  receptor  hER66 increase  the  DNA binding activity  of  Sp1 and Sp3 to  the
COL2A1 first intron
First, to obtain additional information on the ability of 17-E2 and hER66 to modify
Sp1/Sp3-binding sites activity of COL2A1, EMSAs were also performed with the +2817/+2846
COL2A1 radiolabeled oligonucleotide (Fig. 7C). This enhancer probe was already demonstrated
to represent a high affinity binding site for Sp1/Sp3. Two retarded protein-DNA complexes were
previously observed; a major one designated ‘Sp1/Sp3’ and another minor involving Sp3 . As
shown in Fig. 7A, the DNA-binding activity of Sp1 and Sp3 involved in the formation of the first
complex was found to be increased by 17-E2 in a dose-dependent manner in primary RAC. To a
lesser extent, the specific binding activity of Sp3 was also increased by the hormone as reflected
by the modulation of the second ‘Sp3 complex’. Moreover, a strictly similar pattern also applied
for 3-passages dedifferentiated chondrocytes (Fig. 7B).
Secondly, the presence of ER and its binding specificity in articular chondrocytes were
validated by EMSAs experiments  using a consensus ERE or mutated ERE probes and RAC
nuclear extracts incubated or not with antibody directed against ER (Fig. 8). As shown in Fig.
8A, forced expression of hER66 was effective and its binding is specific as demonstrated by
the  addition  of  a  molar  excess  of  cold  wild-type  ERE probe  that  decreases  the  binding  of
hER66. The specificity was also evidenced by using a mutated ERE probe in direct binding
experiments leading to the prevention of hER66 binding. Furthermore, addition of a hER66
antibody provoked a huge decrease in the hER66/probe complex, indicating that this nuclear
receptor is involved in the formation of such a complex. In the same sense, hER66 binding is
increased in dedifferentiated chondrocytes under 17-E2 exposure and it was also specific (Fig.
8B).
Altogether, these EMSAs assays indicate that 17-E2  and hER66 enhance transcription
of COL2A1 by increasing the binding activity of Sp1 and to a lesser extent of Sp3, not only to
COL2A1 promoter but also to COL2A1 specific enhancer.
17-E2 increases the binding activity of the Sox proteins to the COL2A1 specific enhancer
Since IGF-I stimulatory effects on COL2A1 transcription have been already shown by our
laboratory to be mediated by an increase in DNA binding activity of Sox-9/Sox-6/L-Sox-5 to
their functional cis elements in the enhancer of the gene , EMSAs analyses were performed using
the +2353/+2415 bp (4 HMG (‘High Mobility Group’) binding sites) or +2383/+2415 bp (Sox-9
cis-elements and one HMG binding site only) probes (Fig. 9C). As shown in Fig. 9A and 9B, the
binding activity of Sox-9/Sox-6/L-Sox-5 involved in the formation of the different complexes
was  found  to  be  increased  by  17-E2 in  primary  articular  chondrocytes  as  well  as  in
dedifferentiated chondrocytes. By contrast to transient transfection data obtained with reporter
construct pGL2-3.316 kb, these last  results suggest that Sox-9/Sox-6/L-Sox-5, as well  as the
COL2A1 enhancer region, might also participate in the anabolic effect of 17-E2 on COL2A1 in
primary and dedifferentiated chondrocytes since the hormone significantly increases their DNA-
binding activity to this region.
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Sp1, Sp3 or Sox-9 siRNAs prevent hER66-induced stimulation of Col2a1 gene expression
To  finally  demonstrate  that  Sp1,  Sp3  and  Sox-9  proteins  are  required  for  hER66-
induced up-regulation  of  type  II  collagen expression,  we knocked-down their  expression  by
siRNAs experiments. First,  hER66 produced a  3-fold increase in type II collagen mRNAs
steady-state levels under control and 17-E2-treated conditions (Fig. 10A and 10B). Next, we
verified the siRNAs efficiency to silence Sp1, Sp3 and Sox-9 expression by RT-PCR analysis
(Supplemental Fig. 1A). As expected, cell transfection with Sp1 siRNA produced a decrease of
about  65%  of  Sp1  mRNAs  levels  in  the  control  and  17-E2-treated  samples.  In  parallel,
endogenous Sp3 and Sox-9 silencing was accompanied by an important down-regulation of Sp3
and Sox-9 mRNAs levels (about 75% in presence of 17-E2 and 90% in its absence). Then, the
effect of Sp1, Sp3 and Sox-9 silencing on hER66-induced activation of Col2a1 expression was
evaluated (Fig. 10A and 10B). Our data demonstrate that Sp1, Sp3 and Sox-9 siRNAs inhibit
hER66-induced stimulation of type II collagen mRNAs steady-state levels, in presence or not of
17-E2,  providing further  evidence that  these factors play a  central  role  to mediate  hER66
stimulation of  COL2A1 transcription in articular chondrocytes. Additionally, the efficiency of
hER66  overexpression  in  RAC  was  effective  (Supplemental  Fig.  1B),  in  agreement  with
previous experiments (Fig. 4C). 
Sp1 interacts with ER66 and Sp3 in primary articular chondrocytes
Since  ER66  appears  as  a  key  regulatory  factor  in  the  modulation  of  DNA-binding
activity of Sp  trans factors to  COL2A1, we therefore investigated the potential protein-protein
interactions between these factors by immunoprecipitation (IP) experiments using an anti-Sp1
antibody. First, ER66 was found to physically interact with Sp1, independently of the presence
of 17-E2 (Fig. 11A). Furthermore, Sp1 was also co-immunoprecipitated with Sp3 (Fig. 11Bi
and 11Bii) in the same conditions. Western blots were carried out with an anti-Sp1 antibody and
a negative IgG, as positive and negative controls of the assay, respectively (Fig. 11C and 11D).
Additionally,  nuclear  extracts  bound  to  pre-cleared  protein  A-Sepharose  beads,  protein  A-
Sepharose beads incubated with an anti-Sp1 antibody in absence of nuclear extracts, and finally,
protein A-Sepharose beads incubated with nuclear extracts in absence of anti-Sp1 antibody were
also loaded on SDS-PAGE gel as a supplementary control of antibodies specificity (Fig. 11Bii).
All together, these data strongly support the hypothesis that ER66 can regulate type II collagen
expression  by  physically  interacting  with  a  heteromeric  Sp1/Sp3  complex  and  therefore,
modulating Sp1/Sp3 DNA-binding activity to COL2A1.
ER66, Sp1, Sp3 and Sox-9 proteins interact and bind to Col2a1 promoter in vivo
Computer sequence analysis of COL2A1 has revealed that the promoter region did not
contain ERE binding sites (data not shown). Therefore, in order to confirm our in vitro data and
to determine if ER66 was effectively implicated in the regulation of  COL2A1 by 17-E2, we
further clarified ER66 involvement by ChIP assays. Experimental results demonstrated for the
first time that, despite the absence of ERE binding sites, ER66 can be recruited in vivo onto the
Col2a1 short  promoter  in  primary and dedifferentiated  articular  chondrocytes  (Fig.  12A and
12B). Similar amounts of ER66 seem to be recruited onto the promoter both in control and
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17-E2-treated  conditions.  As expected,  Sp1 and Sp3 factors  also bind  to  Col2a1 promoter,
confirming our previous work . Moreover, although type II collagen gene promoter does not
contain  HMG-like  binding sites,  we demonstrated  that  Sox-9 was  able  to  bind indirectly  to
Col2a1 promoter in primary RAC, via protein-protein interactions with Sp1/Sp3 (this study and
reference ) and/or changes in spatial conformation/folding between the intronic enhancer and the
promoter of the gene (Fig. 13). The PCR primers used in ChIP assays map the -119/+52 bp
region of COL2A1 promoter, including three specific Sp cis-elements (-119/-112 bp, -81/-74 bp
and -41/-33 bp).
To further demonstrate if an interaction between ER66 and these three  trans factors
could be effective  on  Col2a1 promoter,  Re-ChIP assays  were performed using  an anti-ER
antibody. As shown in Fig.  12D, Sp1, Sp3 and Sox-9 were always recruited onto the  Col2a1
promoter  after  specific  protein  interaction  with  ER66  receptor.  When  the  dedifferentiated
chondrocytes  are  incubated  in  the  presence  of  17-E2,  although  Sp1 was  still  bound to  the
Col2a1 promoter in the same amounts, it seems that lower amounts of Sp3 and Sox-9 interact
with this sequence compared to the control conditions. These novel findings strongly suggest that
an ER66/Sp1/Sp3/Sox-9 heteromeric  complex formation  could  be necessary to mediate  the
stimulatory effect of 17-E2 on type II collagen gene expression (Fig.13).
ER66, Sp1, Sp3 and Sox-9 proteins interact and bind to Col2a1 first intron in vivo
As previously suggested in EMSAs experiments carried out with  COL2A1 first intron
probes (Fig. 7 and Fig. 9), a multimeric complex composed of ER66/Sp1/Sp3/Sox-9/L-Sox-5
and Sox-6 transcription factors could interact on the COL2A1 enhancer region to mediate 17-
E2-induced COL2A1 transactivation. Therefore, in order to validate our in vitro hypothesis and to
determine whether these transcription factors were effectively able to bind  in vivo to  Col2a1
specific enhancer, we performed ChIP assays in primary chondrocytes using primers mapping
the +2383/+2611 bp region of  COL2A1 first intron. This region includes a Sox-9  cis-element
(+2384/+2404 bp), one HMG binding site (+2388/+2394 bp) and one Sp1/Sp3 binding sequence
(+2440/+2485 bp) but does not harbor ERE  cis-sequence. After PCR amplification, a 229 bp
fragment was observed in samples that were immunoprecipitated with anti-Sp1, anti-Sp3, and
anti-Sox-9  antibodies,  demonstrating  that  these  factors  are  recruited  on  endogenous
+2383/+2611 bp region of Col2a1 (Fig. 12C). Furthermore, we demonstrated, for the first time,
that despite the absence of ERE cis-sequences, ER66 is also recruited in vivo onto the Col2a1
enhancer in articular chondrocytes. 
As  COL2A1 does  not  contain  any ERE region,  ER66 necessarily  interacts  with  the
+2383/+2611 bp Col2a1 enhancer in an indirect way. To identify what protein partners could be
involved  in  the  ER66 recruitment,  we performed  Re-ChIP experiments  using  an  anti-ER
antibody.  Our  data  showed  that  ER66  was  bound  indirectly  to  Col2a1 enhancer  through
protein-protein interactions with Sp1, Sp3 and Sox-9 transcription factors in primary as well as
dedifferentiated articular  chondrocytes  (Fig. 12D). As expected,  and since  COL2A1 enhancer
region does not represent a binding site for RNA polymerase II, even though some molecules of
RNA polymerase II are transcripting the gene, ER66 does not interact with this enzyme. These
results suggest that ER66 acts in concert with Sp1, Sp3 and Sox-9 transcription factors to bind
the +2383/+2611 bp region of Col2a1 enhancer in vivo.
13
p300 is also involved in the regulation of Col2a1 transcription by ER66
Presumably, the ER66 binding to Sp and Sox proteins induces the recruitment of co-
regulatory  proteins  required  for  transactivation.  Nevertheless,  no  identified  hER66  co-
regulatory  proteins  have  been characterized  in  articular  chondrocytes.  To  further  investigate
whether hER66 co-activators can occupy the same Col2a1 promoter/enhancer together as part
of a complex, we performed a sequential chromatin immunoprecipitation (Re-ChIP) assay using
primers  mapping the -119/+52 bp  COL2A1 promoter  and +2383/+2611 bp enhancer regions.
Chromatin from both primary and dedifferentiated RAC was first immunoprecipitated with an
anti-ER antibody and then with a second antibody directed against p300.  Our results clearly
indicate that ER66 and p300 are present as a complex on the Col2a1 promoter and enhancer
(Fig. 12E). In addition, it seems that  17-E2  increases the protein interactions between ER66
and p300 co-activator on both Col2a1 promoter and enhancer, supporting the stimulatory role of
this hormone on COL2A1 transcription. 
Taken together, these results support a pivotal role for Sp1, Sp3 and Sox-9 proteins in
indirect  ER66  recruitment  on  Col2a1,  and  strongly  suggest  that up-regulation  of  type  II
collagen by 17-E2/ER66 complex  is mediated by these transcription factors which interact




In the degenerative pathologies of cartilage such as OA, alteration of type II collagen
expression is a critical step leading to the loss of differentiated articular chondrocyte phenotype.
From epidemiological and biochemical studies, there is already a substantial evidence for a role
of estrogens in cartilage  matrix  homeostasis.  Nevertheless,  these studies still  do not identify
molecular  mechanisms  by  which  articular  chondrocytes  or  synoviocytes  might  be  directly
impacted by low levels of 17-E2. 
The main novel findings of the present  study were that  ER66-induced activation of
COL2A1 transcription is mediated by Sp1/Sp3 together with Sox-9 and euchromatin associated
factors such as p300, and that these factors are recruited in vivo both to the first intron specific
enhancer  and  to  the  promoter  region,  the  two  major  regulatory  regions  of  this  gene. We
particularly investigated and compared the effects mediated by 17-E2 and its receptor ER66 on
type II collagen expression in primary and dedifferentiated articular chondrocytes. In view of the
contradictory reports concerning the action of the hormone on the ECM components, we first
focused on the biological effect of 17-E2 on type II collagen production in chondrocytes. Our
results demonstrate that 17-E2 stimulates type II collagen neosynthesis  and  Col2a1 mRNAs
steady-state  levels  in  primary  RAC,  suggesting  that  17-E2 acts  at  the  transcriptional  level
through a genomic pathway mediated by ER66. Furthermore, because of a possible autocrine
TGF-β stimulation in mediating 17β-E2 activity on type II collagen, we have evaluated the dose-
response effect of 17β-E2 on the gene expression of TGF-β1 and TGF-β type II receptor (TβRII),
known as some of the major  components  of the TGF-β system which play key roles in  the
physiopathology of articular chondrocytes. 17β-E2 at concentrations ranging from 0.01 to 5 nM
is not able to modulate the steady-state amounts of the transcripts encoding TGF-β1 and TβRII
(data not shown), whereas this estrogen enhances the Col2a1 mRNA amounts between 1 and 5
nM. These results  suggest that  eventhough 17β-E2 was demonstrated in other cell  models  to
induce  TGF-β expression  that  could  in  turn  modulate  target  genes  expression,  the  observed
induction  of  type  II  collagen  in  our  study does  not  seem to be  mediated  through autocrine
stimulation of TGF-β in articular chondrocytes.    
In a second time, because of a putative 17-E2 genomic action mediated by ER66, we
focused on the transcriptional action of this receptor on  COL2A1 regulation. The present data
revealed that hER66-induced stimulation of  COL2A1 activity is mediated by the -266/-63 bp
promoter  region.  From a  transcriptional  point  of  view,  nucleotide  sequence  analysis  of  this
promoter  region revealed six C-Krox/Sp1/Sp3-binding sites ;  in particular  two of them were
specific  for  Sp  proteins  (-119/-112  bp  and  -81/-74  bp).  Our  particular  interest  for  hER66
function in articular chondrocytes comes from the fact that this receptor has been previously
described as a partner of Sp1, a key transactivator of  COL2A1, in several different cell lines .
Indeed, the interaction of hER66 with other transcription factors such as AP-1, NF-B and Sp1
which, in turn, bind their cognate DNA elements, modulates gene expression and transcription
factors activity by stabilizing DNA-protein complexes and/or recruiting co-activators . Our data
established that hER66 interacts physically with Sp1 in chondrocytes. This is in agreement with
the observations of Porter et al.  who showed that the major site of interaction of hER66 with
Sp1 protein is associated with the C-terminal DNA-binding domain of Sp1, which is a region
within  Sp1  that  can  also  bind  a  multitude  of  other  transcription  factors,  including  steroid
hormone  receptors  such  as  progesterone  or  androgen  receptors  .  In  addition,  hER66/Sp1
complex can activate transcription through a consensus GC-rich Sp1 binding site in transient
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transfection studies in MCF-7 human breast cancer cells, and this response is also observed with
hER66 variants lacking the DNA-binding domain . 
In our cellular model, we demonstrated that ER66 increases the DNA binding activity
of  Sp1  and,  to  a  lesser  extent,  of  Sp3  to  the  COL2A1 promoter  and  enhancer,  in  both
differentiated and dedifferentiated chondrocytes. Interestingly, in primary RAC, we also found
that 17-E2 increases significantly Sp1 protein levels in a biphasic manner without affecting Sp3
protein expression, except for a 10 nM concentration (Supplemental Fig.2). Similar results were
observed in dedifferentiated RAC for Sp1 protein levels whereas protein expression of long (110
kDa) and short (70 kDa) Sp3 isoforms is significantly reduced, in a dose-dependent manner,
following 17-E2  treatment. These results indicate therefore that ER66 increases the Sp1/Sp3
ratio; which is in accordance with the positive effect of 17-E2 on type II collagen expression
levels  at low or medium-range concentrations. For high concentration treatment, it is possible
that the strong inhibition of Sp1 expression by 17β-E2  while Sp3 expression is more slightly
reduced, may lead to a reduction in the Sp1/Sp3  ratio  and therefore to a suppression of the
stimulatory effect on type II collagen expression. This ‘dose-related effect’ may be due in part to
the  ability  of  17-E2 to  modulate  differentially  Sp1  and  Sp3  protein  levels  in  articular
chondrocytes. Indeed, Sp1/Sp3 modulation has already been shown as a critical parameter for the
regulation  of  COL2A1 transcription:  for  instance,  a  decrease of  Sp1/Sp3 ratio  is  required to
mediate IL-1, interleukin-6 and TGF-1 inhibition of  COL2A1 transcription in RAC . So far,
interactions  of  ER66  with  other  Sp  proteins  different  from  Sp1  have  not  been  well
characterized;  however,  ER66  interacts  with  multiple  domains  of  Sp3.  Interestingly,  the
interacting domains of both proteins are different from those previously observed for interactions
between Sp1 and hER protein . Thus, the ability of ER66 to differentially modulate DNA-
binding activity of these Sp proteins could be explained, in part, by the capacity of ER66 to
bind different domains of Sp proteins. Furthermore, the present work, together with previous
results  from  our  laboratory  ,  established  that  Sp1  and  Sp3  proteins  interact  each  other  in
chondrocytes.  Taken together,  these data strongly suggest that a heteromeric Sp1/Sp3/ER66
complex could mediate the transactivating effect of 17-E2 on COL2A1 promoter. These results
are in  agreement  with those obtained  by  Schultz  et  al.   who  reported  that  hER66 confers
estrogen responsiveness to the progesterone gene by enhancing Sp1 interaction with a ‘GC box’
in the -80/-34 bp region of the human progesterone gene. 
By ChIP assays, we showed for the first time that ER66 indirectly binds to -119/+52 bp
sequence of the  Col2a1 promoter  in primary or dedifferentiated chondrocytes.  Higgins  et al.
showed  that  hER66  is  constitutively  associated  with  17-E2-responsive  GC-rich  promoter
elements that also bind Sp1, Sp3 and Sp4 factors. We demonstrated here the DNA binding of
ER66  in  combination  with  Sp1  and  Sp3  factors  to  the  -119/+52  bp  promoter  region  of
COL2A1, which includes three specific Sp  cis-elements (-119/-112 bp, -81/-74 bp and -41/-33
bp). Thus, these ChIP data combined with transient transfection experiments of COL2A1 reporter
vectors  indicate  that  the  two upstream Sp binding sites  mediate  the hER66 transactivating
effect in both primary and dedifferentiated chondrocytes. Besides, despite the absence of HMG-
like binding sites in type II collagen gene promoter, Sox-9 also binds indirectly to the -119/+52
bp  Col2a1 region in primary RAC (this  study and reference  ).  This transcription  factor was
demonstrated to be an activator of  COL2A1 transcription . Sox9 is co-expressed with type II
collagen during chondrogenesis in the mouse and in cultured chondrocytes, and has been shown
to be absolutely essential for early events in chondrocyte differentiation  and for expression of
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the cartilage-specific matrix genes in human articular chondrocytes . In addition, it was recently
demonstrated  through the  development  and use  of  mice  misexpressing  Sox-9  specifically  in
hypertrophic  chondrocytes  that  Sox-9  is  an  important  negative  regulator  of  cartilage
vascularisation and endochondral ossification .  
Concerning the enhancer region, we reported for the first time an indirect interaction between
ER66  and  the  +2383/+2611  Col2a1 sequence  in  both  primary  and  dedifferentiated
chondrocytes. Our EMSAs analysis clearly indicated that 17-E2 increased Sox-9, Sox-6 and L-
Sox-5 DNA-binding to their cis-elements in the first intron of COL2A1, strongly suggesting that
this region was involved in the up-regulation of COL2A1 by the hormone. Moreover, Re-ChIP
experiments demonstrated that ER66/Sp1, ER66/Sp3 and ER66/Sox-9 complexes were all
recruited onto the  Col2a1 promoter and enhancer in the presence or the absence of 17-E2. In
dedifferentiated  RAC,  Sp3  recruitment  to  the  Col2a1 gene  seemed  to  be  decreased  after
interaction with ER66 following exposure to the hormone. This modulation could be a way by
which  ER66  may  finely  regulate  the  DNA-binding  activity  of  the  well-known  Sp1/Sp3
heteromer and favor Sp1 recruitment to the detriment of Sp3 leading to the  transactivation of
COL2A1. Finally, from our siRNAs experiments, we deduced that inhibition of Sp1, Sp3 or Sox-
9 expression was sufficient to prevent hER66-induced stimulation of  Col2a1 mRNA levels.
Interestingly, some of our previous experiments revealed that Sp1 is an activator of Sox9 DNA
binding activity and Sox9 gene transcription in chondrocytes, but reciprocal combination is also
effective,  i.e. Sox9  increases  the  transcription  of  Sp1 gene  .  Therefore,  considering  that
transcription factors are known to act in concert, it is conceivable that 17-E2 in vivo effect could
be mediated by a bridging complex,  composed of ER66, Sp1, Sp3, Sox-9 and certainly of
several other transcription factors, which could establish a physical link between the two main
transregulatory  regions  of  the  gene,  i.e. the  proximal  promoter  and  the  first  intron,  and
consequently, may facilitate chromatin decondensation and its accessibility to the transcriptional
machinery in  order to  initiate  transcription  process (Fig.  13).  Indeed,  a  relationship  between
COL2A1 promoter and first intron is required for type II collagen expression in cartilage during
chondrogenesis .  It has been reported that the expression of a human COL2A1 transgene in a
mouse model  is governed by a 309-bp enhancer intronic fragment (+2388 to +2696 bp) and
requires the presence of a 90-bp promoter region for tissue-specific expression in the developing
cartilaginous skeleton . Hence, stimulation of the synthesis and/or binding activity by 17-E2 of
one of  the  transcription  factors  involved in  this  main  molecular  complex,  may facilitate  the
formation of a ‘loop structure’ and would increase type II collagen gene expression in RAC.
Despite their different transcriptional functions, Sp1 and Sp3 generally compete for the
same  DNA-binding  sites.  They  form  homotypic  and  heterotypic  complexes  with  numerous
transcriptional  co-regulators which determine the role of Sp proteins as either  transcriptional
activators or repressors. Presumably, ER66 binding to Sp proteins induces recruitment of co-
regulatory proteins required for the transactivation. Thus, the mechanism proposed to explain
17-E2 transactivating effect in chondrocytes is related to the interaction of its receptor hER66
with co-activators, such as steroid receptor co-activators (SRC), CREB binding protein (CBP) or
p300. To date, no identified hER66 co-regulatory proteins have been characterized in articular
chondrocytes.  Nevertheless,  our  Re-ChIP  experiments  performed  on  Col2a1 promoter  and
enhancer raised the hypothesis that p300 is the major co-activator of ER66 in both primary and
dedifferentiated RAC. ER66-p300 interactions on Col2a1 are significantly increased following
17
17-E2  stimulation,  which may contribute to  COL2A1 transactivation.  Indeed, p300  acts as a
bridging factor  to  form multicomponent  complexes  and connects  DNA-binding transcription
factors to the transcription machinery. Furthermore,  p300 is known to interact directly with the
AF-2  domain  and  can  potentiate  the  synergistic  activity  that  results  from  AF-1  and  AF-2
interaction by facilitating binding of TATA binding protein (TBP) on estrogen target promoters .
Otherwise, p300/CBP also presents an intrinsic histone acetyltranferase activity and facilitates
the action of associated transcription factors by modulating histone acetylation.  For instance,
p300  amplifies  stimulatory  effects  of  Sox-9  during  chondrogenesis.  Additionally,  p300
physically binds to C-terminal activation domain of Sox-9, and acts in synergy with this one to
activate  COL2A1 transcription  by  connecting  its  specific  enhancer  sequences  with  the
transcription initiation complex . Thus, we may postulate without ambiguity that ER66 acts as a
co-activator/linker  in  a  transcription  factor  crosstalk  between  Sp/Sox  proteins  and other  co-
activators such as p300 or SRC-3 in articular chondrocytes.
As  demonstrated  by  using  the  AF-1  dominant  negative  action  of  hER46,  the
transcriptional  activation  of  human COL2A1 by  hER66  requires  the  AF-1  transactivation
domain  of  the  receptor.  Moreover,  preliminary  studies  from  our  laboratory  using  hER66
mutants harboring progressive deletions of A/B domain indicate that the entire AF-1 domain (i.e.
Box1, Box2 and Box3) is  required for hER66-induced type  II  collagen mRNA stimulation
(Supplemental Fig. 3A and 3B). Corroborating these results, several studies clearly demonstrated
the importance of AF-1 activity in the estrogenic induction of genes, as well as the requirement
of AF-1 region for full hER66 activity . For example,  the progressive deletion of the AF-1
domain of hER66 leads to a corresponding decrease in the activity of the MMP-13 promoter .
The AF-1 domain is well characterized as the ligand independent transactivation domain of the
hER66  and  synergizes  with  the  AF-2  domain  to  elicit  the  overall  estrogen  response  on
promoters.  Nevertheless,  recent  data from Billon-Gales  et al.  reported that  AF-1 domain of
hER66 is completely dispensable for mediating the major atheroprotective effects of estrogens
using a mouse model missing the hER66 A/B domains. This discrepancy between our results
and this last study could be in part explained by the fact that the respective contribution of AF-1
and AF-2 to the transcriptional activity of the full-length hER66 varies in a promoter and cell
type specific manner . As our results failed to show a stimulatory transactivity when hER46
expression vector is used, we can postulate that the AF-1 domain of hER66 probably plays the
major positive regulatory role in modulating the activity of COL2A1 promoter/enhancer. 
In order to better understand the exact role of hER46 isoform, additional experiments
were performed,  where primary RAC were co-transfected with hERα66 expression vector in
combination with increasing amounts of hERα46 expression vector. These data show for the first
time that hER46 has the ability to repress hER66-induced Col2a1and Sp1 gene expression in
a dose-dependent manner in primary articular chondrocytes (Supplemental Fig. 4). In vivo, both
isoforms  are  frequently  co-expressed.  In  this  situation,  hER46  efficiently  represses  the
transcription of estradiol-target genes induced by hER66 by suppressing AF-1 activity of full-
length estrogen receptor [25]. In terms of transcription, we can postulate that hER46 competes
with hER66 for its binding to Sp1 and Soxs proteins on both the promoter and the first intron of
Col2a1 gene and prevents hER66 from binding to these factors and exerting its stimulatory
effect on  Col2a1 transcription. However, since we observed a faint but significant stimulatory
effect of hER46 on type II collagen synthesis in collagenase and Western-blot assays, a weaker
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positive regulatory role can likely be assigned to AF-2 domain too. Additionally, our data reveal
that the deletion of any of the functional domains of hER66 suppresses the positive regulatory
effect of this receptor on Col2a1 transcription, indicating that all of these functional domains are
indispensable in hER66 action (Supplemental Fig. 3). In addition, as the transfection of hER-
deleted isoforms also decreases Sp1 mRNA levels, this confirms that the receptor involves Sp1
in its regulation of Col2a1 gene. Altogether, our results demonstrate that articular chondrocytes
are mainly sensitive to the AF-1 function of hER66, however, with low permissiveness to AF-
2.
Another novel and relevant finding in our study is that 17-E2 as well as hER66 are able
to  increase  and  therefore  reactivate  type  II  procollagen  expression  in  dedifferentiated  RAC
through a transcriptional control of type II collagen by increasing the DNA binding activities of
Sp1 and Sox9 to their cis responsive elements in COL2A1. In fact, we previously demonstrated
that  these  two  transcription  activators  are  able  to  allow  recovering,  at  least  in  part,  of  the
differentiated phenotype in dedifferentiated cells . For example, Sp1 is an activator of COL2A1
transcription in differentiated and dedifferentiated chondrocytes,  mediating at least the partial
recovery of chondrocyte phenotype, once it has been lost . Besides, our previous study showed
that 17-E2 and hER66 stimulate UDP-glucose dehydrogenase gene activity in primary rabbit
articular  chondrocytes  .  Consequently,  17-E2  would  be  not  only  able  to  reactivate  type  II
collagen  expression  in  dedifferentiated  chondrocytes  but  could  also  elicit  a  cellular
redifferentiation through an increased glycosaminoglycans synthesis in these cells. As stem cells
used for cartilage repair seem to have a similar fate as chondrocytes that drive endochondral
ossification, making the repair tissue inadequate for normal joint function, our data are therefore
attractive in view of the estrogens use in articular cartilage engineering.
Preliminary studies from our laboratory indicate that changes within the respective levels
of expression of hER isoforms are likely to occur during chondrocyte dedifferentiation process
(data not shown), as it already occurs in MCF-7 cell line where hER66/hER46 ratios change
with the cell growth status . Recent works indicate that differences in the expression of hER
isoforms can influence gene regulation and cell growth and/or apoptosis . Alterned expression of
hER66/hER46 may account  for  differential  effects  of  17-E2  on COL2A1 expression and
could explain the differential sensitivity of type II collagen protein to 17-E2 in dedifferentiated
chondrocytes where lower doses of 17-E2 activate type II collagen protein production compared
to  primary  RAC.  This  differential  effect  could  also  be  explained  by the  fact  that  limitative
quantities Sp1 and Sox-9 are present in dedifferentiated RAC and therefore high doses of 17-E2
fail to mobilize supplementary quantities of such transcription factors to activate transcription
more. Besides, Webb et al.  have demonstrated that the more differentiated a cell is, the more
likely  it  will  use  the  AF-1  domain  of  hER66  to  mediate  estrogen  responses,  and
dedifferentiated cells tend to depend more on AF-2 domain of hER66. Nevertheless, from a
transcriptional point of view, we observed similar results of hER66 or hER46 on COL2A1
transcriptional activity between primary and dedifferentiated chondrocytes. This is why further
studies  are  now  required  to  clarify  the  potential  changes  in  hER66/hER46  ratio  during
chondrocyte dedifferentiation and OA process.
Our IP and Re-ChIP data showed that unliganded hER66, is associated with Sp protein,
bound  to  Col2a1 and  addition  of  17-E2  does  not  significantly  alter  the  ER66  promoter
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interactions. Previous studies have confirmed that hER66 could interact with Sp proteins in the
absence  of  ligand  .  Nevertheless,  estrogens  can  be  synthesized  locally  from androgens  via
aromatase  suggesting that the intracrine pathway contributes, beside the known endocrine one,
to the estrogens production in articular chondrocytes. This hypothesis is supported by a study of
Richette  et al.  who showed that 17-E2  is present in human synovial fluid from OA joints, at
concentrations  closely reflecting serum levels.  We may postulate  that  estrogens produced by
chondrocytes  or  synovial  tissues,  acting  both  as  autocrine  or  paracrine  regulators  of  ECM
components  synthesis,  could have a profound effect  on the development  of  OA; so that  the
increased incidence of OA in postmenopausal women might thus be explained by a decrease in
local estrogen concentrations, because 17-E2 has been shown to have anti-erosion properties at
physiological levels.
In summary, our data further corroborate that 17-E2 and its receptor ER66 are critical
actors in  COL2A1 transcriptional regulation; making them motivating targets in order to better
understand the OA dedifferentiation process and facilitate the recovery of differentiated articular
cartilage in osteoarthritic chondrocytes. Such insights are needed not only to implement our basic
understanding of articular  cartilage biology,  but also to help developing novel and improved
strategies for cartilage repair and treatments for degenerative diseases such as OA. From this
point of view, the use of this hormone and/or its nuclear receptor in the tissue engineering of
articular cartilage could be a promising strategy in order to repair this tissue.
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Figure legends
Figure 1: Schematic representation of the human COL2A1 gene. Localization of binding sites
of some of the transcription factors which have been characterized to interact with the promoter
or the enhancer region (in the first intron) of  COL2A1. CIIS: Type II collagen silencer; TBP,
TATA  Binding  Protein;  C/EBP,  CCAAT  Enhancer  Binding  Protein;  NFYA,  Nuclear
transcription Factor Y . 
Figure  2:  Effect  of  17-E2,  hER66  and  hER46  on  collagen  neosynthesis  in  primary
chondrocytes. A, Collagen radiolabeling assay on both medium and cell extract fractions from
primary  RAC cultured  for  24 h in  the  presence  or  absence  of  TGF-,  IL-1 or  17-E2.  B,
Collagen radiolabeling assay on primary RAC transiently transfected with hER66 or hER46
cDNA. The values, normalized to the amount of total protein, were expressed as percentage of
the control (absence of 17-E2 (A) or empty pCR3.1 plasmid (B)) and represent the mean ± S.D.
of  three  (A)  and  four  (B)  independent experiments  performed  in  triplicate.  Statistically
significance was assessed by using the Student’s  t  test and differences were set at  ***p<0.001,
**p<0.01 and *p<0.05. 
Figure 3: Effect of  17-E2, hER66 and hER46 on type II collagen protein expression in
primary  and  dedifferentiated  RAC. A,  Primary  chondrocytes  were  treated  with  increasing
concentrations of 17-E2  for 24 h and type II collagen expression  was assayed using Western-
blotting  analysis  of  whole  cell  extracts.  -actin  was  used  as  a  loading  control.  The  same
experiment as in A was performed on dedifferentiated articular chondrocytes (B) or on primary
RAC  transiently  transfected  with  hER66  or  hER46  expression  vectors  (C).  Histograms
represent the relative expression of type II procollagen normalized to -actin protein signal and
estimated  after  densitometric  analysis  of  the  blots  using  the  Image  J  software.  Results  are
representative of two (B) and three (A and C) independent experiments.
Figure 4: Effect of 17-E2 and hER66 on the steady-state levels of type II collagen mRNAs
in primary chondrocytes. A, Real-time RT-PCR analysis of  Col2a1 mRNAs expression using
total RNAs isolated from primary RAC, treated or not with increasing concentrations of 17β-E2
for 24 h. Results were normalized to 18S rRNAs. B, Primary RAC were treated or not for 24 h
with tamoxifen (Tam.), a partial antagonist of estrogen receptors in our model, and assayed for
real-time  RT-PCR  analysis.  C,  Articular  chondrocytes  were  transiently  transfected  with
increasing amounts of hER66 expression vector and Col2a1 expression was measured by real-
time RT-PCR. Results were normalized to glyceraldehyde 3-phospho dehydrogenase (GAPDH)
mRNAs. D, Verification of hER66 overexpression using specific primers for the long isoform
of human estrogen receptor.  Results  are representative of three independent  experiments  and
values are the means ± S.D. of triplicate samples. Statistically significance was assessed by using
the Student’s t test and differences were set at ***p<0.001, **p<0.01 and *p<0.05.
Figure 5: Effect of 17-E2, hER66, hER46 and ER siRNA on the transcription activity of
human COL2A1 in cultured chondrocytes. Luciferase  assays  on primary (A)  or 3-passages
dedifferentiated  (B)  chondrocytes  transiently  transfected  with  different  COL2A1 reporter
constructs  together  with  either  hER66  (wild  type)  or  hER46  (mutated  isoform).
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Transcriptional activities of each construct were corrected for protein amounts.  C, Luciferase
assays on primary chondrocytes transiently transfected with 10 µg of pGL2-0.387 kb reporter
construct (covering the -266/+121 bp sequence of COL2A1) together with 2 µg of ER siRNA
(siER).  Results  represent  the  mean  ±  S.D.  of  triplicate  samples.  D,  Primary  RAC  were
incubated for 24 h with 17β-E2 (1 nM), mithramycin A (Mith.,  100 nM) or both and type II
collagen mRNA expression was assayed by RT-PCR as described under Materials and Methods.
Values  are  the  means  of  two independent  experiments  performed in  triplicate.  CIIS,  type  II
collagen  silencers.  Statistically  significance  was  assessed  by  using  the  Student’s  t  test  and
differences were set at ***p<0.001, **p<0.01 and *p<0.05.
Figure 6: 17-E2 increases the DNA binding activity of Sp1 and Sp3 to the COL2A1 promoter.
A, Electrophoretic mobility shift assays (EMSAs) were performed using the 5’ end-radiolabeled
-96/-66  COL2A1 probe, incubated with nuclear extracts (NE) from primary RAC treated with
increasing  concentrations  of  17b-E2 for  24 h.  Negative  controls  lacking  nuclear  extracts  are
shown (probe). Sp1/Sp3 and Sp3 protein-DNA complexes are indicated by an arrow. B, EMSAs
were performed as described in A, using the 5’ end-radiolabeled -225/-188 COL2A1 probe.  C,
Sequences of the -96/-66 and -225/-188 COL2A1 radiolabeled probes used. Sp1/Sp3 binding site
is highlighted in bold characters.  
Figure 7: Effect of 17-E2, hER66 and hER46 on the DNA binding activity of Sp1 and Sp3
to the COL2A1 enhancer. A, Electrophoretic mobility shift assays (EMSAs) were performed
using the 5’ end-radiolabeled +2817/+2846 COL2A1 probe, incubated with nuclear extracts (NE)
from primary RAC transfected with either hERa66 or hERa46 expression vectors or treated with
increasing amounts of 17b-E2 for 24 h. B, 3-passages dedifferentiated RAC were incubated with
increasing concentrations of  17b-E2 for 24 h and resulting nuclear extracts were analyzed by
EMSA as described in A. Negative controls lacking nuclear extracts are shown (probe). Sp1/Sp3
and Sp3 protein-DNA complexes are indicated by an arrow. Nuclear extracts from MCF-7 cell
line were also used as control.  C, Sequence of the +2817/+2846  COL2A1 radiolabeled probe
used. Sp1/Sp3 binding site is highlighted in bold characters.  
Figure  8:  A,  ER66  binds  specifically  to  an  ERE consensus  probe  in  primary  articular
chondrocytes. EMSA analysis  was carried  out  with  the nuclear  extracts  from primary  RAC
transfected with either  10 µg of the expression vector hERa66 or hERa46.  Double-stranded
radiolabeled  wild-type  ERE consensus  or  mutant  ERE  probes  were  incubated  with nuclear
extracts (10 µg) in the presence or absence of ER antibody (4 µg) or molar excesses ( 100) of
wild type nonlabeled ERE probe (cold probe). Negative controls lacking nuclear extracts  are
shown (probe). ER-DNA complexes are indicated by an arrow. Nuclear extracts (NE) from
MCF-7 cell line (positive cells for estrogen receptors hERa) were also used as control. B, 17-
E2 increases ER DNA-binding to an ERE consensus probe in dedifferentiated chondrocytes.
Three-passages dedifferentiated RAC were incubated with  17b-E2 for 24 h at  concentrations
ranging from 0 to 10 nM and resulting nuclear extracts were analyzed by EMSA as described in
A.
Figure 9:  17-E2 enhances the binding activity of the Sox proteins to the +2353/+2415 and
+2383/+2415 sequences of the COL2A1 enhancer. A and B, EMSA analysis was carried out
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with the 5’ end-radiolabeled +2353/+2415 (four Sox DNA binding sites) or +2383/+2415 (two
Sox DNA binding sites) COL2A1 double-stranded probes incubated with nuclear extracts from
primary (A) or dedifferentiated (B) articular chondrocytes  treated with increasing amounts of
17b-E2  for  24  h.  Protein-DNA  complexes  are  indicated  by  an  arrow.  C,  Sequences  of  the
+2353/+2415  and  +2383/+2415  COL2A1 radiolabeled  probes  used.  HMG  binding  sites  are
highlighted in bold characters.  
Figure 10: Sp1, Sp3 and Sox-9 siRNAs prevent the hER66-induced stimulation of type II
collagen  mRNA expression. Primary  RAC were  transfected  with  2  µg  of  siRNAs  directed
against Sp1, Sp3 or Sox-9 (respectively siSp1, siSp3 and siSox-9) in combination with 5 µg of
hER66 expression vector. After an overnight transfection period, the cells were incubated for
24 h in the presence (B)  or absence (A)  of 17-E2.  At the end of the experiment,  RT-PCR
analysis  of  Col2a1 mRNA  expression  was  performed  and  expression  of  type  II  collagen
transcripts was normalized to  GAPDH mRNA.  Results are representative of two independent
experiments and each represents the mean ± S.D. of triplicate samples.  Statistically significant
differences relative to the controls pCR3.1 plasmid (denoted by *) or to hER66 expression vector
(denoted  by  )  were  obtained  by  the  Student’s  t  test  (***p<0.001,**p<0.01,   p<0.001  and
p<0.01).
Figure 11: ERa66 and Sp3 transcription factors interact with Sp1 in the nucleus of primary
articular  chondrocytes. Nuclear  extracts  from primary  chondrocytes  cultured  in  presence  or
absence of 17b-E2 for 24 h were submitted to immunoprecipitation (IP) procedure with anti-Sp1
antibody (IP Sp1). Immunoprecipitated complexes were incubated 2 h with protein A-Sepharose
beads and then, submitted to Western-blotting (W.B.) in order to detect ERa (A) and Sp3 (Bi)
proteins. Twenty µg of nuclear extracts, which were not submitted to IP (W.B. w/o IP), were also
loaded onto SDS-PAGE gels.  Bii,  As a supplementary control of the specificity,  a Western-
blotting experiment using an anti-Sp3 antibody was performed on nuclear extracts bound to pre-
cleared protein A-Sepharose beads, on protein A-Sepharose beads incubated with an anti-Sp1
antibody in absence of nuclear extracts and finally, on protein A-Sepharose beads incubated with
nuclear  extracts  in  absence  of  anti-Sp1  antibody.  Positive  and  negative  controls  of  the
experiment  were  realized  by  immunoprecipitating  Sp1  and  submitting  immunoprecipitated
complexes  to Western-blotting using an anti-Sp1 antibody (C,  positive  control)  and IgG (D,
negative control). 
Figure 12: ERa66, Sp1, Sp3, Sox-9 and p300 interact  in vivo on the  Col2a1 promoter and
enhancer. Chromatin immunoprecipitation (ChIP) assays were performed on primary (A, C) or
3-passages dedifferentiated (B)  rabbit  articular  chondrocytes  (RAC) incubated in presence or
absence of 1 nM 17-E2 for 24 h, according to the manufacturer’s instructions. Resulting DNA
was submitted  to  PCR analysis  (40 cycles)  using specific  primers  flanking the -119/+52 bp
Col2a1 region (A, B) or the +2383/+2611 bp Col2a1 region (C). PCR products were separated
on a 2.5% agarose gel and visualized by UV-illumination following ethidium bromide staining.
As positive control, the same primers were used on the genomic DNA (Input) and DNA samples
immunoprecipitated  with  anti-RNA  polymerase  II  antibody  (RNA  pol.  II).  Non  specific
immunoglobulin antibody (IgG) was used as negative control. D and E, In order to perform Re-
ChIP experiments, the sheared chromatin isolated from primary or dedifferentiated chondrocytes
was first immunoprecipitated with 6 µg of antibody directed against ER, followed by a second
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IP using antibodies raised against Sp1, Sp3 and Sox-9 (D) or p300 (E).  The released DNA,
treated with proteinase K, was amplified by PCR (35 cycles) using specific primers flanking
-119/+52 bp Col2a1 region or +2383/+2611 bp Col2a1 region and visualized as described above.
IP, immunoprecipitation; C, control. 
Figure 13: Schematic representation of 17-E2 and hER66 genomic pathway involved in the
up-regulation of type II collagen gene in articular chondrocytes. COL2A1 does not contain
ERE binding sites, so that hER66 interacts with COL2A1 promoter in a non classical genomic
pathway involving protein-protein interactions with transcription factors Sp1, Sp3 and Sox-9.
Some co-activators such as p300 are also involved in the transactivation process of COL2A1.
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